Pharmaceutical Expenditure And Policies

Abstract

All Health Working Papers are now available through the OECD's Internet Website at http://www.oecd.org/els/health-systems/health-working-papers.htm JT03394302 Complete document available on OLIS in its original formatThis document and any map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. This series is designed to make available to a wider readership selected health studies prepared for use within the OECD. Authorship is usually collective, but principal writers are named. The papers are generally available only in their original language -English or French -with a summary in the other.The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli authorities. The use of such data by the OECD is without prejudice to the status of the Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the terms of international law.This document and any map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. ABSTRACTAcross OECD countries, pharmaceutical spending reached around USD 800 billion in 2013, accounting for about 20% of total health spending on average when pharmaceutical consumption in hospital is added to the purchase of pharmaceutical drugs in the retail sector. This paper looks at recent trends in pharmaceutical spending across OECD countries. It examines the drivers of recent spending trends, highlighting differences across therapeutic classes. While the consumption of medicines continues to increase and to push pharmaceutical spending up, cost-containment policies and patent expiries of a number of top-selling products have exerted downward pressure on pharmaceutical expenditures in recent years. This resulted in a slower pace of growth over the past decade.The paper then looks at emerging challenges for policy makers in the management of pharmaceutical spending. The proliferation of high-cost specialty medicines will be a major driver of health spending growth in the coming years. While some of these medicines bring great benefits to patients, others provide only marginal improvements. This challenges the efficiency of pharmaceutical spending.

Gasto farmacéutico en España y medidas de contención

“…A título de ejemplo, el consumo de fármacos antihipertensivos en España se situaba, en 2000, en algo más de 150 dosis diarias definidas (DDD) por 1.000 habitantes y año y aumentó hasta las 269 DDD /1.000 habitantes/año en 2013, mientras que la media de la OCDE fue superior: 190 aproximadamente y 318 DDD/1.000 habitantes/año respectivamente 5 . Sin embargo, la Sociedad Española de Cardiología, a través de la Fundación Española del Corazón, ha difundido los datos de mortalidad atribuible a las enfermedades hipertensivas alertando de que el número de fallecimientos se ha doblado en los últi-mos 10 años, pasando de 6.661, en 2005, a 12.674, en 2015.…”

“…Centrándonos en el gasto con cargo al SNS, la comparación con otros países nos muestra que Luxemburgo (0,51%), Holanda (0,79%), Italia (0,64%), Austria (0,86%), Suecia (0,63%), Suiza (0,73%), Dinamarca (0,32%) o Noruega (0,34%) presentan un consumo menor mientras que Grecia (1,53%), Eslovenia (1,39%), Francia (1,20%), Alemania (1,18%) 5 . En definitiva, de los datos mostrados no se deduce que el gasto farmacéutico público sea grande en nuestro país.…”

Relevancia de práctica de actividad físico-deportiva en personas con VIH

“…Como resultado, la cuota de mercado de los productos genéricos creció rápidamente durante la pasada década, alcanzando el 48 % del total del mercado reembolsable en volumen en 2015, respecto al 14 % en 2005 (gráfico 15). Además, los precios de los genéricos han descendido en un 25 % desde 2008 y se impuso otro descuento para todos los medicamentos cubiertos por el SNS para la asistencia en régimen ambulatorio e interno (Belloni, Morgan y Paris, 2016). El fomento de una mejor distribución geográfica y el mantenimiento de los trabajadores sanitarios en sus empleos suponen un desafío…”

Cell line access to revolutionize the biosimilars market

“…The importance of biologics in both clinical and economic terms continues to grow 1 . At the same time, biologics are notoriously expensive, and challenges in affordability remain even after the expiry of monopoly rights.…”